Trials / Unknown
UnknownNCT04675463
The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD
An Open Label, Single-center, Prospective, Interventional Pilot Study to Evaluate the Effects of Inhaled Budesonide-formoterol-glycopyrronium and Formoterol-glycopyrronium in Moderate-to-severe Chronic Obstructive Pulmonary Disease
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- ShiYue Li · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The fixed-dose combination product Budesonide/Glycopyrronium/Formoterol Fumarate Inhalation Aerosol, BGF pMDI and dual combination product Glycopyrronium/Formoterol Fumarate Inhalation Aerosol , GFF pMDI are developed for maintenance treatment for patients with COPD. There are still some unmet medical needs and evidence gaps in COPD therapy, such as could BGF Inhalation Aerosphere reverse the disease progression such like airway-remodelling? Could BGF Inhalation Aerosphere reduce inflammation in small airways? Before differences proven between medication groups, pilot study is needed. This 52 weeks, Single-center, prospective, interventional pilot study could help discovering intervention effect of BGF and GFF on small airways through OCT measurement, which would show outcome of AEROSPHERE™ Delivery Technology on COPD patients.
Detailed description
The subjects eligible for this study will receive a 52-week of BGF or GFF treatment, and a 30 days follow-up telephone call after the last study drug dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGF Inhalation Aerosphere | Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time |
| DRUG | GFF Inhalation Aerosphere | Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time |
Timeline
- Start date
- 2020-12-30
- Primary completion
- 2023-01-30
- Completion
- 2023-06-30
- First posted
- 2020-12-19
- Last updated
- 2020-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04675463. Inclusion in this directory is not an endorsement.